Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

NILCO biomarkers in breast cancer from Chinese patients

Authors: Laronna S Colbert, Kaamilah Wilson, Sungjin Kim, Yuan Liu, Gabriela Oprea-Ilies, Corey Gillespie, Toi Dickson, Gale Newman, Ruben Rene Gonzalez-Perez

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Notch, IL-1 and leptin are known pro-angiogenic factors linked to breast cancer development, tumor aggressiveness and poor prognosis. A complex crosstalk between these molecules (NILCO) has been reported in breast cancer cell lines. However, whether NILCO biomarkers are differentially expressed in estrogen responsive (ER+), unresponsive (ER-) and triple negative (TNBC) breast cancer tissues is unknown.

Methods

Expression levels of nine NILCO and targets [Notch1, Notch4, JAG1, DLL4, VEGF, VEGFR2 (FLK-1), leptin, leptin receptor (OB-R) and interleukin-1 receptor type I (IL-1R tI)] were examined via immunohistochemistry in breast cancer tissue microarrays from Chinese patients (ER+, n=33; ER-, n=21; TNBC, n=13) and non-malignant breast tissue (n=5; Pantomics, Inc.) using a semi-quantitative analysis of intensity staining, HSCORE.

Results

Categorical expression of NILCO and targets (+ or -) was similar among all cancer tissues. However, TNBC showed differential localization pattern of NILCO. TNBC showed fewer nuclei and cytoplasms positive for Notch4 and JAG1, but more cytoplasms positive for leptin. In addition, fewer TNBC stromas were positive for Notch1 and Notch4, but 100% of TNBC stromas were positive for VEGFR2. Moreover, TNBC had lower DLL4 and IL-1R tI expression. TNBC and ER- showed higher expression of EGFR, but lower expression of AR. Leptin and OB-R were detected in more than 61% of samples. Leptin positively correlated to OB-R, JAG1, VEGF, and marginally to IL-1R tI. Notch1 positively correlated to IL-1R tI. EGFR and Ki67 were positively associated to Notch1, but no associations of NILCO and targets with p53 were found.

Conclusions

Present data suggest that NILCO components are differentially expressed in breast cancer. TNBC showed distinctive patterns for NILCO expression and localization. The complex crosstalk between leptin, IL-1 and Notch could differentially drive breast cancer growth and angiogenesis. Furthermore, the analysis of NILCO and targets using Pathway Studio9 software (Ariadine Genomics) showed multiple molecular relationships that suggest NILCO has potential prognostic biomarker value in breast cancer.
Appendix
Available only for authorised users
Literature
1.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
2.
Rizzo P, Miao H, D’Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L: Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 2008, 68: 5226-5235. 10.1158/0008-5472.CAN-07-5744.CrossRefPubMedPubMedCentral
3.
Rose DP, Vona-Davis L: Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas. 2010, 66: 33-38. 10.1016/j.maturitas.2010.01.019.CrossRefPubMed
4.
Newman G, Gonzalez-Perez RR: Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol. 2013, 382 (25): 570-582.PubMed
5.
Mohamed A, Krajewski K, Cakar B, Ma CX: Targeted therapy for breast cancer. Am J Pathol. 2013, 183: 1096-1112. 10.1016/j.ajpath.2013.07.005.CrossRefPubMed
6.
Stylianou S, Clarke BR, Brennan K: Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006, 66: 1517-1525. 10.1158/0008-5472.CAN-05-3054.CrossRefPubMed
7.
Guo S, Liu M, Gonzalez-Perez RR: Role of notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta. 1815, 2011: 197-213.
8.
Shi W, Harris AL: Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia. 2006, 11: 41-52. 10.1007/s10911-006-9011-7.CrossRefPubMed
9.
Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005, 65: 8530-8537. 10.1158/0008-5472.CAN-05-1069.CrossRefPubMed
10.
Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Sarkar FH: Targeting notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 1806, 2010: 258-267.
11.
Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, Sonenshein G, Osborne BA, Miele L: Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene. 2010, 29: 201-213. 10.1038/onc.2009.323.CrossRefPubMed
12.
Speiser J, Foreman K, Drinka E, Godellas C, Perez C, Salhadar A, Erşahin Ç, Rajan P: Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol. 2012, 20: 139-145.CrossRefPubMed
13.
Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, Hsieh C-C, Altieri DC: A functional Notch–survivin gene signature in basal breast cancer. Breast Cancer Res. 2008, 10: R97-10.1186/bcr2200.CrossRefPubMedPubMedCentral
14.
15.
Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD, Bersch AJ, Holick CN, Hampton JM, Stampfer MJ, Willett WC, Newcomb PA: Body mass index before and after breast cancer diagnosis: associations with All-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev. 2009, 18: 1403-1409. 10.1158/1055-9965.EPI-08-1094.CrossRefPubMedPubMedCentral
16.
Khandekar MJ, Cohen P, Spiegelman BM: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011, 11: 886-895. 10.1038/nrc3174.CrossRefPubMed
17.
Guo S, Gonzalez-Perez RR: Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PloS One. 2011, 6: e21467-10.1371/journal.pone.0021467.CrossRefPubMedPubMedCentral
18.
Gillespie C, Quarshie A, Penichet M, Gonzalez-Perez RR: Potential role of leptin signaling in DMBA-induced mammary tumors by Non-responsive C57BL/6 J mice Fed a high-Fat diet. J Carcinogene Mutagene. 2012, 3: 132-
19.
Battle M, Gillespie C, Quarshie A, Lanier V, Torroella-Kouri M, Gonzalez-Perez RR: Obesity induced leptin-Notch signaling axis in breast cancer. Int J Cancer. 2014, 134: 1606-1616.CrossRef
20.
21.
Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, Lynch MP, Rueda BR: Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem. 2006, 281: 26320-26328. 10.1074/jbc.M601991200.CrossRefPubMed
22.
Saxena NK, Vertino PM, Anania FA, Sharma D: Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem. 2007, 282: 13316-13325. 10.1074/jbc.M609798200.CrossRefPubMedPubMedCentral
23.
Ferla R, Bonomi M, Otvos L, Surmacz E: Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects. BMC Cancer. 2011, 11: 303-CrossRefPubMedPubMedCentral
24.
Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR: Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta. 1825, 2012: 207-222.
25.
Gonzalez RR, Leary K, Petrozza JC, Leavis PC: Leptin regulation of interleukin-1 (IL-1) system in endometrial cells. Mol Hum Reprod. 2003, 9: 151-158. 10.1093/molehr/gag022.CrossRefPubMed
26.
Palomino WA, Fuentes A, Gonzalez RR, Gabler F, Boric MA, Vega M, Devoto L: Differential expression of endometrial integrins and progesterone receptor during the window of implantation in normo-ovulatory women treated with clomiphene citrate. Fertil Steril. 2005, 83: 587-593. 10.1016/j.fertnstert.2004.11.020.CrossRefPubMed
27.
28.
Chen X, Zha X, Chen W, Zhu T, Qiu J, Røe OD, Li J, Wang Z, Yin Y: Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer. Biomed Pharmacother. 2013, 67: 22-30.CrossRefPubMed
29.
Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, Montanaro D, Maggiolini M, Panno ML, Ando S: Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem. 2004, 279: 19908-19915. 10.1074/jbc.M313191200.CrossRefPubMed
30.
Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, Sharma D: Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin induced migration of breast carcinoma cells. Endocr Relat Cancer. 2011, 18: 413-428. 10.1530/ERC-11-0075.CrossRefPubMedPubMedCentral
31.
Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H: Leptin augments proliferation of breast cancer cells via transactivation of HER2. Surg Res. 2008, 149: 9-14. 10.1016/j.jss.2007.10.012.CrossRef
32.
Giordano C, Vizza D, Panza S, Barone I, Bonofiglio D, Lanzino M, Sisci D, De Amicis F, Fuqua SA, Catalano S, Andò S: Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol. 2013, 7: 379-391. 10.1016/j.molonc.2012.11.002.CrossRefPubMed
33.
Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O’Regan RM, Sharma D: Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 2008, 68: 9712-9722. 10.1158/0008-5472.CAN-08-1952.CrossRefPubMedPubMedCentral
34.
Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML: Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 2009, 11: R36-10.1186/bcr2321.CrossRefPubMedPubMedCentral
35.
Otvos L, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E: Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 2011, 10: 1578-1584.CrossRef
36.
Speiser J, Foreman K, Drinka E, Godellas C, Perez C, Salhadar A, Erşahin Ç, Rajan P: Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol. 2012, 20: 139-145.CrossRefPubMed
37.
Kim SB, Chae GW, Lee J, Park J, Tak H, Chung JH, Park TG, Ahn JK, Joe CO: Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation. Cell Death Differ. 2007, 14: 982-991.PubMed
38.
Dong Y, Li A, Wang J, Weber JD, Michel LS: Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res. 2010, 70: 5465-5474. 10.1158/0008-5472.CAN-10-0173.CrossRefPubMed
39.
Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, Hursting SD, Rich JN, Hjelmeland AB, Vasanji A, Berger NA, Lathia JD, Reizes O: Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer. 2013, 20: 797-808. 10.1530/ERC-13-0329.CrossRefPubMedPubMedCentral
40.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003, 348: 1625-1638. 10.1056/NEJMoa021423.CrossRefPubMed
41.
Feldman DE, Chen C, Punj V, Tsukamoto H, Machida K: Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci U S A. 2012, 109: 829-834. 10.1073/pnas.1114438109.CrossRefPubMed
42.
Gilbert CA, Slingerland JM: Cytokines, Obesity, and Cancer: New Insights on Mechanisms Linking Obesity to Cancer Risk and Progression. Ann Rev Med. 2013, 64: 45-57. 10.1146/annurev-med-121211-091527.CrossRefPubMed
43.
Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, Bustos M, Martinez JA, Moreno-Aliaga MJ: Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta. 1807, 2011: 664-678.
44.
45.
Wang Y, Mi J, Shan XY, Wang QJ, Ge KY: Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond). 2007, 1: 177-188.CrossRef
Metadata
Title
NILCO biomarkers in breast cancer from Chinese patients
Authors
Laronna S Colbert
Kaamilah Wilson
Sungjin Kim
Yuan Liu
Gabriela Oprea-Ilies
Corey Gillespie
Toi Dickson
Gale Newman
Ruben Rene Gonzalez-Perez
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-249

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Missed opportunities: racial and neighborhood socioeconomic disparities in emergency colorectal cancer diagnosis and surgery

Research article

The structure and demographic correlates of cancer fear

Research article

Nutrition and lung cancer: a case control study in Iran

Research article

Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients

Research article

Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer

Research article

Is provider type associated with cancer screening and prevention: advanced practice registered nurses, physician assistants, and physicians
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits